Out tonight. RRM
Insulet Enters into Development Agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated Insulin
PR Newswire Insulet Corporation
5 hours ago
BILLERICA, Mass., Jan. 11, 2016 /PRNewswire/ -- Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced it has entered into a development agreement with Eli Lilly and Company (Lilly) to develop a new version of Insulet's OmniPod tubeless insulin delivery system, specifically designed to deliver Lilly's Humalog 200 units/mL insulin. Humalog U200 is a concentrated form of insulin used by higher insulin-requiring patients with diabetes that provides the same dose of insulin in half the volume of Lilly's Humalog U100 insulin. Insulet is partnering with Lilly on a clinical development program designed to evaluate the use of the Humalog U200 insulin formulation in Insulet's leading OmniPod tubeless insulin delivery system.
With a growing population of diabetes patients worldwide requiring higher total daily doses of insulin, this new version of the OmniPod tubeless insulin delivery system will be the first insulin pump designed specifically to deliver Humalog U200 insulin. This new delivery system represents an opportunity for diabetes patients with higher insulin requirements to benefit from the improved glycemic control compared to multiple daily injections and ease of use that Insulet's OmniPod System provides.
"We are thrilled to partner with Lilly to develop the first insulin pump specifically designed for Humalog U200 insulin," said Patrick Sullivan, Chief Executive Officer. "This partnership allows Insulet to deliver the advantages of our OmniPod System to individuals worldwide with higher insulin requirements so they can better control their diabetes. Using Humalog U200 in OmniPod's tubeless design effectively doubles the number of insulin units available to users in a single pod. This will provide the freedom and ease of use of our OmniPod System to a broader range of individuals living with diabetes."
About the OmniPod Insulin Management System:
The OmniPod Insulin Management System is a unique and discreet insulin delivery system designed to provide people living with diabetes the freedom and simplicity that conventional "tubed" insulin pumps and multiple daily injections cannot provide. The OmniPod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove it when showering, swimming or performing other activities. This means that OmniPod can provide up to three days of non-stop insulin delivery without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod's cannula insertion is quick, simple, and virtually pain-free. The user simply pushes a button on the PDM and the Pod's automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user's programmed basal rate.
The OmniPod System is the world's first commercially available tubeless insulin delivery system that allows patients to live untethered to a tubed pump or a daily injection schedule. By breaking down the barriers to insulin pump therapy, the OmniPod System offers freedom for users to live life on their own terms and with the ease of use they deserve.
- Forums
- ASX - By Stock
- UNS
- Lilly
Lilly
-
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online